With a focus on rare diseases and a pipeline of targeted therapies, this commercial-stage company operates at the intersection of scientific innovation and unmet clinical need. Several recent developments make it a stock worth watching in the current market landscape.
Zevra Therapeutics Inc. (ZVRA) develops treatments for conditions such as idiopathic hypersomnia, narcolepsy, vascular Ehlers-Danlos syndrome, and Niemann-Pick Disease Type C. Its commercial portfolio includes AZSTARYS, approved for attention deficit hyperactivity disorder, and OLPRUVA, indicated for certain urea cycle disorders, both currently available in the U.S.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.